Shanghai Pharmaceuticals Holding Full Year 2024 Earnings: Misses Expectations

Simply Wall St

Shanghai Pharmaceuticals Holding (SHSE:601607) Full Year 2024 Results

Key Financial Results

  • Revenue: CN¥274.2b (up 5.8% from FY 2023).
  • Net income: CN¥4.55b (up 21% from FY 2023).
  • Profit margin: 1.7% (up from 1.5% in FY 2023). The increase in margin was driven by higher revenue.
  • EPS: CN¥1.23 (up from CN¥1.02 in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

SHSE:601607 Revenue and Expenses Breakdown April 1st 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Pharmaceuticals Holding Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 2.2%. Earnings per share (EPS) also missed analyst estimates by 7.3%.

The primary driver behind last 12 months revenue was the Sub-Underwriter segment contributing a total revenue of CN¥251.2b (92% of total revenue). Notably, cost of sales worth CN¥244.8b amounted to 89% of total revenue thereby underscoring the impact on earnings. The largest operating expense was Sales & Marketing costs, amounting to CN¥12.6b (51% of total expenses). Explore how 601607's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 9.4% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Healthcare industry in China.

Performance of the Chinese Healthcare industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Be aware that Shanghai Pharmaceuticals Holding is showing 1 warning sign in our investment analysis that you should know about...

Valuation is complex, but we're here to simplify it.

Discover if Shanghai Pharmaceuticals Holding might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.